In the latest move by a country to crack down on anti-competitive behavior by drug makers, Ukrainian regulators fined Sanofi (SNY) approximately $2.6 million for purportedly working with two distributors to restrict competition of dozens of medicines several years ago.

In a decision issued on Tuesday, the Antimonopoly Committee explained that, during 2010 and 2011, the drug maker provided unspecified “conditions and discounts” to the distributors — BadMM and Optimum-Farm — to market Sanofi medicines for which lower-cost generic competition existed.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy